Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Colorcon
Baxter
Merck

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR PROMETHAZINE DM


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Promethazine Dm

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00270777 ↗ Improving Safety of Antivenom in People Bitten by Snakes Completed University of Kelaniya Phase 4 2005-03-01 A study to increase the safety of polyvalent antivenom involving 1000 patients in three centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double blind, placebo-controlled trial.
NCT00293215 ↗ Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen Terminated Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2006-02-01 This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193.
NCT00293215 ↗ Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen Terminated Ludwig Institute for Cancer Research Phase 1 2006-02-01 This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193.
NCT00429832 ↗ A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed GlaxoSmithKline Phase 4 2003-10-01 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00429832 ↗ A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department Completed University of New Mexico Phase 4 2003-10-01 This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department.
NCT00455234 ↗ Rapid Tranquillization Trial: TREC-India II Completed Christian Medical College, Vellore, India Phase 3 2005-09-01 Three hundred consecutive adult patients presenting to the emergency services of the department of psychiatry and who are diagnosed by the treating doctor to be needing tranquillization to control agitated or aggressive behavior will be randomized to receive either Injection Olanzepine I.M. or Injection Haloperidol 10mg + Injection Promethazine 50 mg in this parallel group, block randomized, centrally-randomzed, allocation-concealed, assessor-blinded pragmatic clinical trial. The main outcome measure that the two treatments would be compared on would be the clinical state of the patient 4 hours after intervention, but the rate of tranquillization, degree of sedation, proportions tranquil and / or asleep at 15, 30, 60 and 240 minutes, need for additional medication, use of physical restraints, doctors called back, numbers absconding and adverse effects at each of these time points would also be compared. Compliance with oral medication and adverse effects at the end of 2 weeks would also be compared.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Promethazine Dm

Condition Name

Condition Name for Promethazine Dm
Intervention Trials
Nausea 10
Pain 5
Vomiting 5
Postoperative Nausea and Vomiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Promethazine Dm
Intervention Trials
Nausea 18
Vomiting 15
Postoperative Nausea and Vomiting 8
Emergencies 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Promethazine Dm

Trials by Country

Trials by Country for Promethazine Dm
Location Trials
United States 33
Iran, Islamic Republic of 3
Germany 2
Canada 2
Lebanon 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Promethazine Dm
Location Trials
Texas 7
Pennsylvania 6
Tennessee 2
Massachusetts 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Promethazine Dm

Clinical Trial Phase

Clinical Trial Phase for Promethazine Dm
Clinical Trial Phase Trials
Phase 4 17
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Promethazine Dm
Clinical Trial Phase Trials
Completed 31
Terminated 9
Unknown status 6
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Promethazine Dm

Sponsor Name

Sponsor Name for Promethazine Dm
Sponsor Trials
Charleston Laboratories, Inc 5
M.D. Anderson Cancer Center 3
Merck Sharp & Dohme Corp. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Promethazine Dm
Sponsor Trials
Other 59
Industry 14
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
AstraZeneca
Express Scripts
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.